Bolt Biotherapeutics: Coastlands holds 412,416 shares
Warrants become exercisable after stockholder-approved conversion; they expire 30 days after first public disclosure of Program 2 results or June 30, 2028, whichever comes first.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
3
Rhea-AI Filing Summary
Bolt Biotherapeutics, Inc. reports indirect holdings by Coastlands Capital LP dated November 6, 2026: 412,416 shares of common stock, Series D preferred stock convertible into 1,166,275 common shares, and warrants for 583,138 common shares at an $8.5743 exercise price. Each Series D preferred share converts into 1,000 common shares following stockholder approval. Conversion and warrant exercise are subject to a 4.99% beneficial-ownership limit.
Insider Trade Summary
Holdings reported, no transactions
Holdings
Insider
Coastlands Capital LP
Role
10% Owner
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Holding | Series D Non-Voting Convertible Preferred Stock F2, F1 | -- | -- | -- |
| Holding | Warrant F3, F1 | -- | -- | -- |
| Holding | Common Stock F1 | -- | -- | -- |
Holdings:
Series D Non-Voting Convertible Preferred Stock — 1,166,275 contracts (Indirect, By Coastlands Capital LP);
Warrant — 583,138 contracts (Indirect, By Coastlands Capital LP);
Common Stock — 412,416 shares (Indirect, By Coastlands Capital LP)
Footnotes (3)
- F1. Coastlands Capital LP ("Coastlands") and Coastlands Capital GP LLC (the "General Partner") are the investment adviser and general partner, respectively, of Coastlands Capital Partners LP (the "Partnership"). Coastlands Capital LLC ("Coastlands GP") is the general partner of Coastlands. Matthew Perry is the control person of Coastlands, the Partnership, Coastlands GP and the General Partner. The reporting persons are filing this Form 3 jointly, but not as members of a group, and each disclaims membership in a group. Each reporting person also disclaims beneficial ownership of common stock except to the extent of that person's pecuniary interest therein.
- F2. Following stockholder approval of the conversion of Series D Non-Voting Convertible Preferred Stock, par value $0.00001 per share ("Series D Preferred Stock"), into shares of Common Stock and, to the extent deemed necessary or advisable, an increase in the number of authorized shares of Common Stock, each share of Series D Preferred Stock will automatically convert into 1,000 shares of Common Stock, subject to certain limitations. The Series D Preferred Stock has no expiration date. Coastlands may not convert such shares if Coastlands, together with its affiliates, would beneficially own more than 4.99% of the number of shares of Common Stock outstanding immediately after giving effect to such conversion.
- F3. The warrants to purchase shares of the Issuer's common stock (the "Warrants") become exercisable following the automatic conversion of the Series D Preferred Stock into Common Stock upon receipt of the requisite stockholder approval, and expire on the earlier of (i) 30 days following the Issuer's first public disclosure of top-line results from the first-in-human clinical data from its Program 2 Phase 1 (IL-31 bispecific) and (ii) June 30, 2028. Coastlands may not exercise the Warrants if Coastlands, together with its affiliates, would beneficially own more than 4.99% of the number of shares of common stock outstanding immediately after giving effect to such exercise.
Key Figures
Common stock held indirectly: 412,416 shares
Common shares underlying Series D preferred stock: 1,166,275 shares
Common shares underlying warrants: 583,138 shares
+3 more
6 metrics
Common stock held indirectly
412,416 shares
Reported November 6, 2026
Common shares underlying Series D preferred stock
1,166,275 shares
Reported November 6, 2026
Common shares underlying warrants
583,138 shares
Reported November 6, 2026
Warrant exercise price
$8.5743 per share
Warrants to purchase common stock
Common shares per Series D preferred share
1,000 shares
Automatic conversion following stockholder approval
Beneficial-ownership limit
4.99%
Applies to conversion and warrant exercise
Key Terms
Series D Non-Voting Convertible Preferred Stock, beneficially own, first-in-human clinical data
3 terms
Series D Non-Voting Convertible Preferred Stock technical
"each share of Series D Preferred Stock will automatically convert"
beneficially own regulatory
"would beneficially own more than 4.99%"
Beneficially own means having the economic rights and risks of a security—such as the right to receive dividends, sell the shares, or profit from price changes—whether or not your name appears on the official share register. Think of it like renting a car: you use it and reap the benefits even if the title lists someone else. Investors care because beneficial ownership determines who truly controls value, must be disclosed under securities rules, and can signal potential influence or trading activity that affects a stock’s price.
first-in-human clinical data medical
"top-line results from the first-in-human clinical data"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What limits BOLT preferred-stock conversion and warrant exercise?
Each Series D preferred share will automatically convert into 1,000 common shares after stockholder approval, subject to limitations. Conversion and warrant exercise cannot occur if they would result in Coastlands and its affiliates beneficially owning more than 4.99% of common stock outstanding immediately afterward. The warrants become exercisable after the preferred-stock conversion following requisite approval.
AI-generated analysis. How Rhea-AI works. Not financial advice.
